论文部分内容阅读
关于淋巴因子对肿瘤免疫作用的研究,已把重点放在非细胞毒性作用上。直接通过介质产生,或间接通过各种杀伤细胞诱导或放大作用而产生。对比之下,有一种低分子量质(<10,000)的淋巴因子,称为种瘤移动抑制因子(TMIF),在体外它能抑制肿瘤细胞移动,但无毒性作用。经多种标准测试,TMIF 不同于影响炎性细胞或其它非新生物细胞活动的淋巴因子,最近我们证明,TMIE 活性可在患肿瘤的动物血清中发现,也可在适当免疫的动物血清中发现,它在体内可能起保护作用。此实验需要确定一种肿瘤转移模
Research on the role of lymphokines in tumor immunity has focused on non-cytotoxic effects. Produced directly through the medium, or indirectly induced or amplified by various killer cells. In contrast, there is a low molecular weight (<10,000) lymphokine known as the Tumor Mobility Suppressor (TMIF), which inhibits tumor cell migration but has no toxic effects in vitro. TMIF differs from lymphokines that affect the activity of inflammatory cells or other non-neoplastic cells on a variety of criteria and recently we demonstrated that TMIE activity can be found in the serum of tumor-bearing animals as well as in the serum of appropriately immunized animals , It may play a protective role in the body. This experiment needs to identify a model of tumor metastasis